MoonLake Immunotherapeutics (NASDAQ:MLTX)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Trailing Twelve Months EPS: ($0.75)
2024 EPS Estimate: ($1.45)
2025 EPS Estimate: ($2.47)
- Current Stock Price
- $54.04
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 9 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $80.45 (48.9% Upside)
